The content on this site is intended for healthcare professionals only
Dr Garcia-Sanz speaks with ecancer at EHA 23 about the results from a phase I/II trial of treating r/rHL with brentuximab vedotin, along with ESHAP chemo, to improve depth of response ahead of stem cell transplant.
He describes the tolerability of the combination as easily managed, and the overall pre transplant response as 93% including a 71% complete response rate.
Dr Garcia-Sanz highlights these findings are now leading to a phase III trial, with the combination highly effective at inducing remission before transplant.
KRdc as induction therapy shows improved OS for NDMM patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
